Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.8.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2017
Nov. 30, 2016
Nov. 30, 2017
Nov. 30, 2016
Operating expenses:        
General and administrative $ 1,608,743 $ 1,679,925 $ 3,178,420 $ 3,259,988
Research and development 9,077,172 4,383,636 17,225,348 8,069,109
Amortization and depreciation 89,136 92,556 178,282 185,140
Total operating expenses 10,775,051 6,156,117 20,582,050 11,514,237
Operating loss (10,775,051) (6,156,117) (20,582,050) (11,514,237)
Interest income 422 5,648 1,206 9,383
Change in fair value of derivative liability 829,600 1,223,466 466,934 1,223,466
Interest expense:        
Amortization of discount on convertible notes (728,843)   (1,172,995)  
Amortization of debt issuance costs (168,429)   (282,129)  
Interest related to derivative liability   (540,333)   (540,333)
Inducement interest related to warrant exercise     (826,252)  
Interest on convertible notes payable (105,384)   (180,673)  
Total interest expense (1,002,656) (540,333) (2,462,049) (540,333)
Loss before income taxes (10,947,685) (5,467,336) (22,575,959) (10,821,721)
Provision for taxes on income 0 0 0 0
Net loss $ (10,947,685) $ (5,467,336) $ (22,575,959) $ (10,821,721)
Basic and diluted loss per share $ (0.07) $ (0.04) $ (0.15) $ (0.08)
Basic and diluted weighted average common shares outstanding 157,843,773 136,023,544 154,774,327 130,185,627